Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 10/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28014929 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL27820406 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL27820410 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL11052070 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL539143 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2671379 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1690132 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL5183216 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL3285881 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2905315 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023184708-A1 | CYCLODEXTRIN-BASED ETHYL LAUROYL ARGINATE INCLUSION COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京财经大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230293412-A1 | SHAMPOOS AND METHODS OF PREPARING AND USING THE SAME | SHANDONG BENZHEN COSMETICS CO., LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4114381-A2 | CATIONIC SURFACTANTS, IN PARTICULAR ETHYL LAUROYL ARGINATE LAE®, FOR TREATING OR PREVENTING INFECTIONS AND CONTAMINATIONS WITH CORONAVIRUS | Laboratorios Miret, S.A. (ES) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022122627-A3 | CATIONIC SURFACTANTS, IN PARTICULAR ETHYL LAUROYL ARGINATE LAE®, FOR TREATING OR PREVENTING INFECTIONS AND CONTAMINATIONS WITH CORONAVIRUS | LABORATORIOS MIRET, S.A. (ES) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022122627-A2 | CATIONIC SURFACTANTS, IN PARTICULAR ETHYL LAUROYL ARGINATE LAE®, FOR TREATING OR PREVENTING INFECTIONS AND CONTAMINATIONS WITH CORONAVIRUS | LABORATORIOS MIRET, S.A. (ES) | 2022-06-16 | — | — | WO | disclosed |
| EP-3348253-B1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | LACER SA (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3348253-A1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | Lacer, S.A. (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-7714154-B2 | Preparation of amino acid-fatty acid anhydrides | NORTHERN INNOVATIONS AND FORMULATIONS CORP. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7511162-B2 | Preparation of amino acid-fatty acid anhydrides | MULTI FORMULATIONS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| WO-2008138090-A1 | PREPARATION OF AMINO ACID-FATTY ACID ANHYDRIDES | MULTI FORMULATIONS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080281113-A1 | Preparation of amino acid-fatty acid anhydrides | MULTI FORMULATIONS LTD (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080200725-A1 | Enhanced bioavailability; reacting fatty acid and amino acid using thionyl halide | 2462096 ONTARIO LIMITED (CA) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281113-A1 | Preparation of amino acid-fatty acid anhydrides | FABP2, FABP4, FABP1 | DPP7 421/4885GNAI3 3151/4885GNAO1 4134/4885 |
| US-20080200725-A1 | Enhanced bioavailability; reacting fatty acid and amino acid using thionyl halide | FABP2, FABP1, FABP4 | DPP7 489/4885GNAI3 3625/4885GNAO1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.